V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214171 | 20129721 | 1.9 | 117 | Palliative (P) | 2017-06-05 | 2017-06-27 | EOX | 02 | N | TRIAL | 101072474 |
| 20214172 | 20129722 | 1.63 | 97 | null | null | 2021-10-05 | Cetuximab + Oxaliplatin + MdG Maint | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100282417 |
| 20214173 | 20129723 | 1.56 | 76 | Palliative (P) | 2019-04-14 | 2019-06-24 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101137504 |
| 20214174 | 20129724 | 1.8 | 66.8 | Palliative (P) | 2019-09-14 | 2019-09-14 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100590873 |
| 20214175 | 20129725 | 1.56 | 82.4 | Palliative (P) | 2016-10-17 | 2017-08-13 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101822188 |
| 20214177 | 20129726 | 1.57 | 68.1 | null | 2019-06-29 | 2019-07-06 | EOX | N | N | CETUXIMAB + IRINOTECAN + MDG | 101110349 |
| 20214178 | 20129727 | 1.49 | 80.45 | Palliative (P) | 2017-02-24 | 2017-04-08 | EOX | Y | N | CETUXIMAB + IRINOTECAN + MDG | 101725707 |
| 20214182 | 20129728 | 0 | 58 | Neo-adjuvant (N) | 2019-05-28 | 2019-07-18 | IRINOTECAN + MDG + PANITUMUMAB | 02 | Y | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101756387 |
| 20214183 | 20129729 | 1.78 | 107.8 | Palliative (P) | 2018-09-05 | 2018-10-02 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 100664284 |
| 20214186 | 20129730 | 0 | 96.1 | Palliative (P) | 2019-10-10 | 2019-10-23 | Cetuximab + FOLFIRI cycle 2 onwards | 2 | N | CETUXIMAB + IRINOTECAN + MDG | 100825243 |
| 20214187 | 20129731 | 1.63 | 78.3 | Palliative (P) | 2017-02-07 | 2017-02-07 | EOX | 02 | N | SORAFENIB | 100475628 |
| 20214188 | 20129732 | 1.54 | 82.8 | null | 2019-07-13 | 2019-08-03 | EOX | 02 | N | EOX | 101456881 |
| 20214189 | 20129733 | 1.67 | 102.1 | null | 2016-09-17 | 2016-09-27 | Trial Unspecified | 02 | null | TRIAL | 101286964 |
| 20214191 | 20129734 | 1.62 | 65 | null | 2021-10-11 | 2021-11-05 | IRINOTECAN + MDG + PANITUMUMAB | 02 | Y | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101210153 |
| 20214193 | 20129735 | 1.64 | null | Neo-adjuvant (N) | 2018-09-16 | 2018-12-01 | Sorafenib | 02 | N | SORAFENIB | 101363320 |
| 20214194 | 20129736 | 1.93 | 71.5 | null | 2019-10-20 | 2020-02-12 | Oxaliplatin + Raltitrexed | 02 | null | OXALIPLATIN + RALTITREXED | 101517022 |
| 20214196 | 20129737 | 1.71 | 61.4 | Curative (C) | null | 2018-06-28 | Cetuximab + FOLFIRI cycle1 | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101641671 |
| 20214197 | 20129738 | 1.76 | 69.4 | null | 2018-08-25 | 2019-09-09 | CETUXIMAB + IRINOTECAN + MDG | N | null | CETUXIMAB + IRINOTECAN + MDG | 100107624 |
| 20214198 | 20129739 | 1.6 | 67.8 | Palliative (P) | 2020-02-03 | 2020-02-19 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101745448 |
| 20214199 | 20129740 | 1.67 | 70.6 | null | 2017-09-05 | 2017-09-05 | Sorafenib | 02 | Y | SORAFENIB | 100534109 |
| 20214203 | 20129741 | 1.66 | 90 | Palliative (P) | 2019-05-03 | 2019-06-08 | Sorafenib | 02 | null | SORAFENIB | 100899082 |
| 20214204 | 20129742 | 1.57 | 0 | 03 | 2020-01-30 | 2020-03-04 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100771201 |
| 20214205 | 20129743 | 1.6 | 96 | Curative (C) | 2016-12-11 | 2017-01-08 | Oxaliplatin + Raltitrexed | 02 | null | OXALIPLATIN + RALTITREXED | 101794001 |
| 20214206 | 20129744 | null | null | Palliative (P) | 2017-09-12 | 2017-09-27 | EOX | null | N | CETUXIMAB + IRINOTECAN + MDG | 101809770 |
| 20214207 | 20129745 | 1.75 | 91 | Adjuvant (A) | 2016-12-29 | 2017-01-07 | Cetuximab + Oxaliplatin + MdG Maint | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100279314 |
| 20214211 | 20129746 | 1.81 | 84 | Palliative (P) | 2020-04-13 | 2020-04-13 | CAPECITABINE + RT | 02 | N | CAPECITABINE + RT | 100292186 |
| 20214216 | 20129747 | 1.71 | 95 | Curative (C) | 2018-06-20 | 2018-07-18 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101466859 |
| 20214218 | 20129748 | null | null | 03 | 2017-04-03 | 2017-05-04 | Trial Unspecified | Y | N | TRIAL | 100698175 |
| 20214219 | 20129749 | 1.58 | 54.6 | Curative (C) | 2019-09-13 | 2019-09-13 | Capecitabine 35days + RT | 02 | N | CAPECITABINE + RT | 101856607 |
| 20214220 | 20129750 | 1.75 | 68.6 | Neo-adjuvant (N) | 2019-05-19 | 2019-05-21 | CAPECITABINE + RT | 02 | N | CAPECITABINE + RT | 101508150 |
| 20214223 | 20129751 | 1.7 | 75 | Palliative (P) | 2017-06-05 | 2018-01-08 | EOX | 2 | N | EOX | 100230760 |
| 20214226 | 20129752 | 1.78 | 76 | null | 2018-01-17 | 2018-01-22 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100279326 |
| 20214227 | 20129753 | 1.74 | 88.2 | Neo-adjuvant (N) | 2019-05-12 | 2019-08-06 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101716428 |
| 20214228 | 20129754 | 1.72 | 77.9 | Adjuvant (A) | 2019-01-15 | 2019-01-21 | Sorafenib | 02 | N | SORAFENIB | 100049192 |
| 20214230 | 20129755 | 1.59 | 69 | null | 2020-12-22 | 2020-12-25 | Panitumumab + Irinotecan + MdG | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101576125 |
| 20214231 | 20129756 | 1.84 | 61 | null | 2021-01-29 | 2021-02-07 | EOX | 2 | null | EOX | 100868147 |
| 20214232 | 20129757 | 1.83 | 65.7 | Palliative (P) | 2016-09-18 | 2016-09-18 | EOX | 02 | N | CAPECITABINE + RT | 101058652 |
| 20214233 | 20129758 | 1.74 | 54.4 | Neo-adjuvant (N) | 2021-01-18 | 2021-01-21 | Sorafenib | 02 | Y | SORAFENIB | 100402158 |
| 20214234 | 20129759 | 1.64 | 18.9 | null | 2018-01-11 | 2018-01-11 | Trial Unspecified | 02 | null | TRIAL | 101216849 |
| 20214237 | 20129760 | 1.84 | 78.7 | Palliative (P) | 2017-10-14 | 2017-10-20 | Trial Unspecified | 02 | N | TRIAL | 100453083 |
| 20214239 | 20129761 | 1.72 | 58.1 | Curative (C) | 2016-03-02 | 2016-05-29 | Sorafenib | 02 | null | SORAFENIB | 101404840 |
| 20214240 | 20129762 | 1.88 | 67 | Palliative (P) | 2018-05-23 | 2018-05-23 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 100319630 |
| 20214241 | 20129763 | 1.66 | 79.4 | Palliative (P) | 2016-06-30 | 2016-07-09 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101363183 |
| 20214242 | 20129764 | 1.69 | 114.4 | Palliative (P) | 2018-05-23 | 2018-05-26 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101248653 |
| 20214243 | 20129765 | 0 | 111.3 | Palliative (P) | 2018-05-06 | 2018-05-11 | EOX | 02 | N | EOX | 100580680 |
| 20214244 | 20129766 | 1.88 | 58.7 | Palliative (P) | 2017-02-01 | 2017-02-08 | EOX | 02 | null | EOX | 101565299 |
| 20214247 | 20129767 | 1.5 | 81.05 | null | 2018-03-18 | 2018-12-13 | EOX | 02 | null | EOX | 101806069 |
| 20214248 | 20129768 | 1.43 | 96 | Neo-adjuvant (N) | 2017-09-16 | 2017-09-22 | EOX | 2 | N | EOX | 101481648 |
| 20214249 | 20129769 | 1.88 | 67.6 | Palliative (P) | 2019-02-21 | 2019-02-28 | Trial Unspecified | 99 | N | TRIAL | 101006441 |
| 20214250 | 20129770 | 1.76 | 51.2 | Curative (C) | 2018-07-19 | 2018-07-19 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101345757 |